Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron?
Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26
More from Archive
More from Pink Sheet
The UK drug regulator is collecting data to establish whether patients who are hospitalized for acute pancreatitis after taking a GLP-1 drug have a genetic predisposition to this side effect. If a “clear link” is found, the MHRA would consider regulatory action.
While titanium dioxide is banned as a food additive in the EU, the European Medicines Agency has convinced the European Commission to allow its continued use in the many thousands of medicines in which it is currently used.
Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.